Matches in Wikidata for { <http://www.wikidata.org/entity/Q90693281> ?p ?o ?g. }
Showing items 1 to 42 of
42
with 100 items per page.
- Q90693281 description "clinical trial" @default.
- Q90693281 description "ensayo clínico" @default.
- Q90693281 description "ensayu clínicu" @default.
- Q90693281 description "klinisch onderzoek" @default.
- Q90693281 description "клінічне випробування" @default.
- Q90693281 name "A Study of Nivolumab and Ipilimumab in Combination With Transarterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer" @default.
- Q90693281 name "A Study of Nivolumab and Ipilimumab in Combination With Transarterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer" @default.
- Q90693281 type Item @default.
- Q90693281 label "A Study of Nivolumab and Ipilimumab in Combination With Transarterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer" @default.
- Q90693281 label "A Study of Nivolumab and Ipilimumab in Combination With Transarterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer" @default.
- Q90693281 prefLabel "A Study of Nivolumab and Ipilimumab in Combination With Transarterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer" @default.
- Q90693281 prefLabel "A Study of Nivolumab and Ipilimumab in Combination With Transarterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer" @default.
- Q90693281 P1132 Q90693281-7C0F3D1A-2140-4BE9-9268-2E419B679DD0 @default.
- Q90693281 P1476 Q90693281-F0CA7366-049B-4BB7-808C-39513356C7EC @default.
- Q90693281 P17 Q90693281-29E9BD33-8C6F-4D02-9ADF-6F220D6EE14E @default.
- Q90693281 P17 Q90693281-51E3E89C-242B-4378-A8D8-8B6241209C04 @default.
- Q90693281 P1813 Q90693281-9BC4E251-EEA6-45C5-9CAB-D6A780702761 @default.
- Q90693281 P2899 Q90693281-534D71C1-EFB3-4F1C-9664-1A43673BB5D1 @default.
- Q90693281 P3098 Q90693281-A773D757-FEC9-4D26-ADDC-1153A0602BE2 @default.
- Q90693281 P31 Q90693281-2556DDF6-34C0-4DF4-9E86-E53D8B402F33 @default.
- Q90693281 P4844 Q90693281-A9B8EE42-5137-4FEA-9CF5-1F9FE0D3E8DD @default.
- Q90693281 P4844 Q90693281-E31BC89B-0CA5-4BA6-8D17-236B3F8E5176 @default.
- Q90693281 P580 Q90693281-01DC0D6E-CDC5-4BCA-8E7B-25B1F2127539 @default.
- Q90693281 P582 Q90693281-78F33454-A762-4A07-99F2-BC6C94BC4EC8 @default.
- Q90693281 P6099 Q90693281-3297339E-5BCE-4B59-8CA7-DB4E90761533 @default.
- Q90693281 P8363 Q90693281-C8E3C51D-0E70-4BEE-9E03-8DDE8E373ACF @default.
- Q90693281 P859 Q90693281-E1C0E6DC-2DF3-4347-9082-147E81CBBB8B @default.
- Q90693281 P1132 "+765" @default.
- Q90693281 P1476 "A Randomized, Multi-center, Double-blinded, Placebo-controlled Phase 3 Study of Nivolumab and Ipilimumab, Nivolumab Monotherapy, or Placebo in Combination With Trans-arterial ChemoEmbolization (TACE) in Patients With Intermediate-stage Hepatocellular Carcinoma (HCC)" @default.
- Q90693281 P17 Q183 @default.
- Q90693281 P17 Q408 @default.
- Q90693281 P1813 "CheckMate 74W" @default.
- Q90693281 P2899 "+18" @default.
- Q90693281 P3098 "NCT04340193" @default.
- Q90693281 P31 Q30612 @default.
- Q90693281 P4844 Q2459042 @default.
- Q90693281 P4844 Q7041828 @default.
- Q90693281 P580 "2020-05-28T00:00:00Z" @default.
- Q90693281 P582 "2025-06-29T00:00:00Z" @default.
- Q90693281 P6099 Q42824827 @default.
- Q90693281 P8363 Q78089383 @default.
- Q90693281 P859 Q266423 @default.